Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of March 31, 2019 and December 31, 2018 are as follows:

			As of March 31, 2019			As of December 31, 2018
			(unaudited)
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Diagnostic assets:
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		18,351			18,351
Total			$	43,011		$	43,011
Diagnostic lab:
CLIA Lab		2.3	$	609		$	609
Accumulated Amortization			$	(14,580	)	$	(10,515	)
Net Carrying Value			$	29,040		$	33,105

Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

2019		2020		2021		2022		2023
$	3,252	$	4,272	$	4,908	$	2,987	$	2,987